PDGFRB and hepatocellular carcinoma: To date, sorafenib (Nexavar), a multikinase inhibitor targeting RAF serine/threonine kinases, and VEGFR1-3, PDGFR beta (PDGFRβ), and RAS/RAF/MEK/ERK signaling pathways, is the first approved molecular-targeted agent that demonstrated survival benefits in patients with advanced HCC in a 2007 study [6].